Dr. Vanden Bossche,
I have been following you since March of this year. I appreciate all that you have been doing. I have a serious question for you. I’ve read the Andrew Read study on Marek’s disease Vaccines Are Pushing Pathogens to Evolve | Quanta Magazine.
But this statement you made below, for me, needs to be clarified.
“…allosteric mutations and ADE, remember? It’s ADE that is going to tip the balance in the wrong and irreversible direction. ADE in vaccinees will provide the virus with exceptional virulence and make it resemble Marek in unvaccinated”
“ADE in vaccinees will provide the virus with exceptional virulence and make it “RESEMBLE” Marek in unvaccinated.” Could you please clarify:
In other words, does your concern have any relevance, in this context, for the unvaccinated? Perhaps I’m being too fine in my reading of the transcript, but to me it is a bit confusing. My reading of your writings has lead me to assume that you are more concerned about the vaccinees than the unvaccinated, so I don’t want to be wrong in repeating your warnings.
In the READ study it was clear that the unvaccinated chickens got the worst of it from the ADE of the vaccinated chickens, which is why I ask the question.
Thanks, in advance, for answering.
What I meant to say is that the level of impact of ADE (Antibody-Dependent Enhancement) on morbidity and mortality in humans vaccinated against Omicron could be similar to that observed in non-vaccinated chickens contracting Marek. While having a protective effect against disease, vaccination against Marek disease using imperfect/ leaky vaccines leads to increased viral virulence (i.e., enhanced morbidity and mortality rate) in unvaccinated chicken. I predict that mass vaccination of humans with imperfect/ leaky C-19 vaccines against Omicron will result in high rates of morbidity and mortality from SARS-CoV-2 in the very vaccinees, especially if treatment protocols keep being disapproved. But symptoms of Marek disease in chicken are, of course, very different from those provoked by an enhanced form of C-19 disease in humans.
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.